Want to see LYEL full AI Analyst Report?
LYEL Stock Chart & Stats
$12.63
-$0.15(-1.17%)
At close: 4:00 PM EDT
$12.63
-$0.15(-1.17%)
Day’s Range― - ―
52-Week Range$9.28 - $45.00
Previous Close$12.63
Volume90.65K
Average Volume (3M)74.95K
Market Cap
$317.82M
Enterprise Value$233.66
Total Cash (Recent Filing)$254.02M
Total Debt (Recent Filing)$48.85M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 12, 2026EPS Estimate
-2.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.98
Shares Outstanding24,504,358
10 Day Avg. Volume75,611
30 Day Avg. Volume74,954
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.12
Price to Sales (P/S)14614.51
P/FCF Ratio-3.49
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$38.80Price Target Upside207.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-7.64
Revenue Forecast (FY)$12.86K
Bulls Say, Bears Say
Bulls Say
Platform-focused R&DLyell’s platform approach—cell engineering, TCR/CAR T programs and manufacturing/reprogramming technology—creates durable optionality across multiple programs. Platform assets can drive repeated value creation, partnerships and manufacturing leverage beyond any single trial outcome over months to years.
Low LeverageSubdued absolute debt and a low debt-to-equity ratio give Lyell structural financial flexibility relative to leveraged peers. Lower interest and refinancing pressure reduces solvency risk and preserves strategic optionality while the company pursues long-duration development milestones.
Governance StabilityStrong shareholder backing for the board, auditor and compensation framework signals governance continuity and investor alignment. Stable leadership and oversight lower execution and fundraising risk, aiding consistent strategy execution and long-term stakeholder coordination.
Bears Say
High Cash BurnSustained, large negative operating and free cash flow indicate the company must access capital repeatedly to fund R&D. Persistent burn drives recurring financing needs and dilution risk, constraining long-term planning and elevating execution risk across 2–6 months absent material partnerships or financings.
Minimal, Declining RevenueAlmost no recurring or product revenue leaves Lyell dependent on collaborations, milestones or financings. Declining near-term revenue reduces any cushioning against cash burn and signals limited commercial traction, increasing reliance on external capital and partner deals for sustainability.
Large Losses And Eroded EquityDeep operating and net losses have materially eroded shareholders’ equity over time, reflecting sustained value consumption. That trend weakens the balance sheet buffer, raises future dilution likelihood, and constrains strategic choices unless R&D progress converts into partnering or financing success.
Lyell Immunopharma News
LYEL FAQ
What was Lyell Immunopharma’s price range in the past 12 months?
Lyell Immunopharma lowest stock price was $9.28 and its highest was $45.00 in the past 12 months.
What is Lyell Immunopharma’s market cap?
Lyell Immunopharma’s market cap is $317.82M.
When is Lyell Immunopharma’s upcoming earnings report date?
Lyell Immunopharma’s upcoming earnings report date is Aug 12, 2026 which is in 12 days.
How were Lyell Immunopharma’s earnings last quarter?
Lyell Immunopharma released its earnings results on May 06, 2026. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.312 by $0.212.
Is Lyell Immunopharma overvalued?
According to Wall Street analysts Lyell Immunopharma’s price is currently Undervalued.
Does Lyell Immunopharma pay dividends?
Lyell Immunopharma does not currently pay dividends.
What is Lyell Immunopharma’s EPS estimate?
Lyell Immunopharma’s EPS estimate is -2.02.
How many shares outstanding does Lyell Immunopharma have?
Lyell Immunopharma has 24,504,358 shares outstanding.
What happened to Lyell Immunopharma’s price movement after its last earnings report?
Lyell Immunopharma reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.312. Following the earnings report the stock price went down -3.789%.
Which hedge fund is a major shareholder of Lyell Immunopharma?
Currently, no hedge funds are holding shares in LYEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lyell Immunopharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$38.80 (207.21% Upside)
$38.80 (207.21% Upside)
Blogger Sentiment
Bullish
LYEL Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 98.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $11.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
106.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-18.42%
Trailing 12-Months
Company Description
Lyell Immunopharma
Lyell Immunopharma, Inc. (LYEL) is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. The company applies cell engineering approaches intended to enhance the durability and function of T cells in the tumor microenvironment, with a pipeline that includes programs in adoptive cell therapy (such as CAR T and TCR-based therapies) and related technology platforms for T-cell reprogramming/manufacturing.
LYEL Stock 12 Month Forecast
Average Price Target
$38.80
▲(207.21% Upside)
Technical Analysis
Rocket Pharmaceuticals
―
Editas Medicine
―
Mereo Biopharma Group Plc
―
Replimune Group
―
―
Ownership Overview
39.42% Insiders
6.98% Mutual Funds
0.04% Other Institutional Investors
47.60% Public Companies and
Individual Investors